



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cagrilintide

Cat. No.:	HY-P3462
CAS No.:	1415456-99-3
Molecular Formula:	C ₁₉₄ H ₃₁₂ N ₅₄ O ₅₉ S ₂
Molecular Weight:	4409.01
Sequence:	{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH ₂ (Disulfide bridge:Cys3-Cys8)
Sequence Shortening:	{Eicosanedioic acid-γ-Glu}-KCNTATCATQRLAEFLRHSSNFGPILPPTNVGSNTP-NH ₂ (Disulfide bridge:Cys3-Cys8)
Target:	CGRP Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

BIOLOGICAL ACTIVITY

Description	Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity ^{[1][2][3]} .																
In Vivo	<p>Cagrilintide (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.) reduces food intake in the rat^[2]. Cagrilintide (10 nmol/kg; i.v. or s.c.) shows good pharmacokinetic parameters^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>12 weeks, 400 g Sprague Dawley male rats^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1, 3, 10, 30 nmol/kg</td> </tr> <tr> <td>Administration:</td> <td>S.c.; once for 80 h</td> </tr> <tr> <td>Result:</td> <td>Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>12 weeks, 400 g Sprague Dawley male rats^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 nmol/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.; s.c.</td> </tr> <tr> <td>Result:</td> <td>Showed good pharmacokinetic parameters with T_{1/2} of 20±2, 27±3 h for i.v. and s.c., respectively.</td> </tr> </table>	Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]	Dosage:	0.1, 1, 3, 10, 30 nmol/kg	Administration:	S.c.; once for 80 h	Result:	Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg.	Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]	Dosage:	10 nmol/kg	Administration:	I.v.; s.c.	Result:	Showed good pharmacokinetic parameters with T _{1/2} of 20±2, 27±3 h for i.v. and s.c., respectively.
Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]																
Dosage:	0.1, 1, 3, 10, 30 nmol/kg																
Administration:	S.c.; once for 80 h																
Result:	Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg.																
Animal Model:	12 weeks, 400 g Sprague Dawley male rats ^[2]																
Dosage:	10 nmol/kg																
Administration:	I.v.; s.c.																
Result:	Showed good pharmacokinetic parameters with T _{1/2} of 20±2, 27±3 h for i.v. and s.c., respectively.																

REFERENCES

- [1]. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. *J Pharmacol Exp Ther.* 2021 Jun;377(3):417-440.
- [2]. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. *J Med Chem.* 2021 Aug 12;64(15):11183-11194.
- [3]. Dehestani B, et al. Amylin as a Future Obesity Treatment. *J Obes Metab Syndr.* 2021 Dec 30;30(4):320-325.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA